[Bisalbuminemia. Review and observations on the acquired form in a patient with myeloma].

V. Pola,M. Tichý

1984-08-01

Abstract:

What problem does this paper attempt to address?

Alpha-1 antitrypsin deficiency: A conformational disease associated with lung and liver manifestations

C. M. Greene,S. D. W. Miller,T. Carroll,C. McLean,M. O'Mahony,M. W. Lawless,S. J. O'Neill,C. C. Taggart,N. G. McElvaney,M. O’Mahony,S. J. O’Neill

DOI: https://doi.org/10.1007/s10545-007-0748-y

IF: 4.7501

2008-01-16

Journal of Inherited Metabolic Disease

Abstract:Alpha-1 antitrypsin (A1AT) is a serine anti-protease produced chiefly by the liver. A1AT deficiency is a genetic disorder characterized by serum levels of less than 11 mumol/L and is associated with liver and lung manifestations. The liver disease, which occurs in up to 15% of A1AT-deficient individuals, is a result of toxic gain-of-function mutations in the A1AT gene, which cause the A1AT protein to fold aberrantly and accumulate in the endoplasmic reticulum of hepatocytes. The lung disease is associated with loss-of-function, specifically decreased anti-protease protection on the airway epithelial surface. The so-called 'Z' mutation in A1AT deficiency encodes a glutamic acid-to-lysine substitution at position 342 in A1AT and is the most common A1AT allele associated with disease. Here we review the current understanding of the molecular pathogenesis of A1AT deficiency and the best clinical management protocols.

genetics & heredity,endocrinology & metabolism,medicine, research & experimental
Late Breaking Abstract - Severe alpha-1 antitrypsin deficiency is associated with increased expression of CD8+ T cell markers

FitzGerald,R.,Herron,M.,Kanchi,L.,Leacy,E.,Heeney,R.,Roche,S.,Carroll,T.,Murphy,M.,Mcelvaney,N. G.

DOI: https://doi.org/10.1183/13993003.congress-2024.pa4412

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Introduction: Alpha-1 antitrypsin (AAT) is an antiprotease and anti-inflammatory glycoprotein. AAT deficiency (AATD) is an autosomal co-dominant condition resulting in low plasma and lung AAT levels. The Z allele is the most common variant that encodes severe AAT deficiency. Consequently, Z homozygote individuals have increased risk of developing early onset COPD. CD8+ T cells, associated with inflammation and cytotoxic markers, are upregulated in COPD. However, the influence of the Z allele on CD8+ T cell markers is less well understood. Aims and objectives: To identify if severe AATD impacts the expression of CD8+ T cell markers. Methods: 20 MM and 20 ZZ individuals underwent time-matched phlebotomy and bronchoalveolar lavage (BAL). These were divided as healthy or COPD, as defined by clinical review, pulmonary function tests and CT of thorax. Multiplex ELISA was performed on matching plasma and BAL to quantify the expression of CD8+ markers (Human CD8/NK Panel V02,13-plex, 741187, Biolegend). Results: IL-4, TNFα, Granzyme A and Granzyme B were significantly upregulated in the plasma of ZZ individuals. In agreement with findings in plasma, IL-4 was significantly upregulated in the BAL of ZZ individuals. Healthy ZZ individuals had significantly higher expression of IL-2, IL-10, IL-6, TNFα and Granzyme B in plasma compared to healthy MM individuals. IL-4 was significantly upregulated in plasma of healthy ZZ compared to MM COPD individuals. Conclusions: The ZZ genotype is associated with increased expression of many CD8+ T cell markers, even in the absence of lung disease. This suggests a potential precursor to COPD and a novel biomarker in alpha-1 antitrypsin deficiency.

respiratory system
Monocyte NLRP3 inflammasome and interleukin-1β activation modulated by alpha-1 antitrypsin therapy in deficient individuals

Debananda Gogoi,Howard Yu,Michelle Casey,Rory Baird,Azeez Yusuf,Luke Forde,Michael E O' Brien,Jesse R West,Tammy Flagg,Noel G McElvaney,Edward Eden,Christian Mueller,Mark L Brantly,Patrick Geraghty,Emer P Reeves

DOI: https://doi.org/10.1136/thorax-2023-221071

2024-02-28

Thorax

Abstract:Introduction Altered complement component 3 (C3) activation in patients with alpha-1 antitrypsin (AAT) deficiency (AATD) has been reported. To understand the potential impact on course of inflammation, the aim of this study was to investigate whether C3d, a cleavage-product of C3, triggers interleukin (IL)-1β secretion via activation of NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome. The objective was to explore the effect of AAT augmentation therapy in patients with AATD on the C3d/complement receptor 3 (CR3) signalling axis of monocytes and on circulating pro-inflammatory markers. Methods Inflammatory mediators were detected in blood from patients with AATD (n=28) and patients with AATD receiving augmentation therapy (n=19). Inflammasome activation and IL-1β secretion were measured in monocytes of patients with AATD, and following C3d stimulation in the presence or absence of CR3 or NLRP3 inhibitors. Results C3d acting via CR3 induces NLRP3 and pro-IL-1β production, and through induction of endoplasmic reticulum (ER) stress and calcium flux, triggers caspase-1 activation and IL-1β secretion. Treatment of individuals with AATD with AAT therapy results in decreased plasma levels of C3d (3.0±1.2 μg/mL vs 1.3±0.5 μg/mL respectively, p<0.0001) and IL-1β (115.4±30 pg/mL vs 73.3±20 pg/mL, respectively, p<0.0001), with a 2.0-fold decrease in monocyte NLRP3 protein expression (p=0.0303), despite continued ER stress activation. Discussion These results provide strong insight into the mechanism of complement-driven inflammation associated with AATD. Although the described variance in C3d and NLRP3 activation decreased post AAT augmentation therapy, results demonstrate persistent C3d and monocyte ER stress, with implications for new therapeutics and clinical practice.

respiratory system
Alpha-defensins inhibit ERK/STAT3 signaling during monocyte-macrophage differentiation and impede macrophage function

Jungnam Lee,Naweed Mohammad,Yuanqing Lu,Regina Oshins,Alek Aranyos,Mark Brantly

DOI: https://doi.org/10.1186/s12931-023-02605-0

IF: 5.8

2023-12-12

Respiratory Research

Abstract:Alpha-1-antitrypsin deficiency (AATD) is a genetic disorder associated with a 5–tenfold decrease in lung levels of alpha-1-antitrypsin (AAT) and an increased risk for obstructive lung disease. α-defensins are cationic broad-spectrum cytotoxic and pro-inflammatory peptides found in the azurophilic granules of neutrophils. The concentration of α-defensins is less than 30 nM in the bronchoalveolar lavage fluid of healthy controls but is up to 6 μM in AATD individuals with significant lung function impairment. Alveolar macrophages are generally classified into pro-inflammatory (M1) or anti-inflammatory (M2) subsets that play distinct roles in the initiation and resolution of inflammation. Therefore, monocyte-macrophage differentiation should be tightly controlled to maintain lung integrity. In this study, we determined the effect of α-defensins on monocyte-macrophage differentiation and identified the molecular mechanism of this effect. The results of this study demonstrate that 2.5 μM of α-defensins inhibit the phosphorylation of ERK1/2 and STAT3 and suppress the expression of M2 macrophage markers, CD163 and CD206. In addition, a scratch assay shows that the high concentration of α-defensins inhibits cell movement by ~ 50%, and the phagocytosis assay using flow cytometry shows that α-defensins significantly reduce the bacterial phagocytosis rate of monocyte-derived macrophages (MDMs). To examine whether exogenous AAT is able to alleviate the inhibitory effect of α-defensins on macrophage function, we incubated MDMs with AAT prior to α-defensin treatment and demonstrate that AAT improves the migratory ability and phagocytic ability of MDMs compared with MDMs incubated only with α-defensins. Taken together, this study suggests that a high concentration of α-defensins inhibits the activation of ERK/STAT3 signaling, negatively regulates the expression of M2 macrophage markers, and impairs innate immune function of macrophages.

respiratory system
Impact of Hypoxia on Neutrophil Degranulation and Inflammatory Response in Alpha-1 Antitrypsin Deficiency Patients

María Magallón,Silvia Castillo-Corullón,Lucía Bañuls,Teresa Romero,Daniel Pellicer,Alberto Herrejón,María Mercedes Navarro-García,Cruz González,Francisco Dasí

DOI: https://doi.org/10.3390/antiox13091071

IF: 7.675

2024-09-03

Antioxidants

Abstract:Background: Alpha-1 antitrypsin deficiency (AATD) is an inflammatory disorder where neutrophils play a key role. Excessive neutrophil activation leads to local hypoxia and tissue damage. Most research on neutrophil function has been conducted under atmospheric conditions (21% O2), which may not represent physiological or pathological conditions. This study aimed to determine the effects of hypoxia on neutrophil degranulation and cytokine production in AATD patients. Methods: Neutrophils isolated from 54 AATD patients (31 MZ; 8 SZ; 15 ZZ) and 7 controls (MM) were exposed to hypoxia (1% O2) for 4 h. Neutrophil degranulation was assessed by measuring elastase (NE), myeloperoxidase (MPO), lactoferrin, and matrix metalloproteinase-9 (MMP-9) levels using immunoassay-based methods. Pro-inflammatory (IL-8, IL-1 beta, IL-6, and TNF-alpha) and anti-inflammatory (IL-4 and IL-10) cytokine levels were assessed by a Luminex-based method. Results: Our results indicate a significantly increased release of NE (p = 0.015), MPO (p = 0.042), lactoferrin (p = 0.015), and MMP-9 (p = 0.001) compared to controls. Pro-inflammatory cytokines show a significant rise in IL-8 (p = 0.019), a trend towards increased IL-1 beta (p = 0.3196), no change in IL-6 (p = 0.7329), and reduced TNF-alpha (p = 0.006). Anti-inflammatory cytokines show increased IL-4 (p = 0.057) and decreased IL-10 (p = 0.05703). Conclusions: Increased neutrophil degranulation and inflammatory phenotype are observed in AATD neutrophils under physiological hypoxia.

biochemistry & molecular biology,chemistry, medicinal,food science & technology
Alpha-1 antitrypsin deficiency impairs lung antibacterial immunity in mice

Lena Ostermann,Regina Maus,Jennifer Stolper,Lisanne Schütte,Konstantina Katsarou,Srinu Tumpara,Andreas Pich,Christian Mueller,Sabina Janciauskiene,Tobias Welte,Ulrich A Maus

DOI: https://doi.org/10.1172/jci.insight.140816

IF: 9.4958

2021-02-08

JCI Insight

Abstract:Alpha-1 antitrypsin (AAT) is a major inhibitor of serine proteases in mammals. Therefore, its deficiency leads to protease-antiprotease imbalance and a risk for developing lung emphysema. Although therapy with human plasma-purified AAT attenuates AAT deficiency-related emphysema, its impact on lung antibacterial immunity is poorly defined. Here, we examined the effect of AAT therapy on lung protective immunity in AAT-deficient (KO) mice challenged with Streptococcus pneumoniae. AAT-KO mice were highly susceptible to S. pneumoniae, as determined by severe lobar pneumonia and early mortality. Mechanistically, we found that neutrophil-derived elastase (NE) degraded the opsonophagocytically important collectins, surfactant protein A (SP-A) and D (SP-D), which was accompanied by significantly impaired lung bacterial clearance in S. pneumoniae-infected AAT-KO mice. Treatment of S. pneumoniae-infected AAT-KO mice with human AAT protected SP-A and SP-D from NE-mediated degradation and corrected the pulmonary pathology observed in these mice. Likewise, treatment with Sivelestat, a specific inhibitor of NE, also protected collectins from degradation and significantly decreased bacterial loads in S. pneumoniae-infected AAT-KO mice. Our findings show that NE is responsible for the degradation of lung SP-A and SP-D in AAT-KO mice affecting lung protective immunity in AAT deficiency.
The spectrum of clinical sequelae associated with alpha-1 antitrypsin deficiency

Vickram Tejwani,James K Stoller

DOI: https://doi.org/10.1177/2040622321995691

2021-07-29

Abstract:Alpha-1 antitrypsin (AAT) deficiency (AATD) is an autosomal co-dominant condition that predisposes to the development of lung disease, primarily emphysema. Emphysema results from the breakdown of lung matrix elastin by proteases, including neutrophil elastase, a protease normally inhibited by AAT. AATD also predisposes to liver (cirrhosis) and skin (panniculitis) disease, and to vasculitis. The prevalence of AATD is estimated to be approximately 1 in 3,500 individuals in the United States. However, lack of awareness of AATD among some physicians, misperceptions regarding the absence of effective therapy, and the close overlap in symptoms with asthma and non-AATD chronic obstructive pulmonary disease are thought to contribute to under-recognition of the disease. In patients with AATD, treatment with intravenous AAT augmentation therapy is the only currently available treatment known to slow the progression of emphysema. Moreover, smoking cessation and other lifestyle interventions also help improve outcomes. Early diagnosis and intervention are of key importance due to the irreversible nature of the resultant emphysema. Liver disease is the second leading cause of death among patients with AATD and a minority of patients present with panniculitis or antineutrophil cytoplasmic antibody-associated vasculitis, thought to be directly related to AATD. Though no randomized trial has assessed the effectiveness of augmentation therapy for AATD-associated panniculitis, clinical experience and case series suggest there is a benefit. Other diseases putatively linked to AATD include aneurysmal disease and multiple neurological conditions, although these associations remain speculative in nature.
The Mechanism of Mitochondrial Injury in Alpha-1 Antitrypsin Deficiency Mediated Liver Disease

Nazli Khodayari,Rejean L. Wang,Regina Oshins,Yuanqing Lu,Michael Millett,Alek M. Aranyos,Sayedamin Mostofizadeh,Yogesh Scindia,Tammy O. Flagg,Mark Brantly

DOI: https://doi.org/10.3390/ijms222413255

IF: 5.6

2021-12-09

International Journal of Molecular Sciences

Abstract:Alpha-1 antitrypsin deficiency (AATD) is caused by a single mutation in the SERPINA1 gene, which culminates in the accumulation of misfolded alpha-1 antitrypsin (ZAAT) within the endoplasmic reticulum (ER) of hepatocytes. AATD is associated with liver disease resulting from hepatocyte injury due to ZAAT-mediated toxic gain-of-function and ER stress. There is evidence of mitochondrial damage in AATD-mediated liver disease; however, the mechanism by which hepatocyte retention of aggregated ZAAT leads to mitochondrial injury is unknown. Previous studies have shown that ER stress is associated with both high concentrations of fatty acids and mitochondrial dysfunction in hepatocytes. Using a human AAT transgenic mouse model and hepatocyte cell lines, we show abnormal mitochondrial morphology and function, and dysregulated lipid metabolism, which are associated with hepatic expression and accumulation of ZAAT. We also describe a novel mechanism of ZAAT-mediated mitochondrial dysfunction. We provide evidence that misfolded ZAAT translocates to the mitochondria for degradation. Furthermore, inhibition of ZAAT expression restores the mitochondrial function in ZAAT-expressing hepatocytes. Altogether, our results show that ZAAT aggregation in hepatocytes leads to mitochondrial dysfunction. Our findings suggest a plausible model for AATD liver injury and the possibility of mechanism-based therapeutic interventions for AATD liver disease.

biochemistry & molecular biology,chemistry, multidisciplinary
Cardiovascular disease in Alpha 1 antitrypsin deficiency: an observational study assessing the role of neutrophil proteinase activity and the suitability of validated screening tools

E. Sapey,L. E. Crowley,R. G. Edgar,D. Griffiths,S. Samanta,H. Crisford,C. E. Bolton,J. R. Hurst,R. A. Stockley

DOI: https://doi.org/10.1186/s13023-024-03124-x

2024-03-23

Orphanet Journal of Rare Diseases

Abstract:Alpha 1 Antitrypsin Deficiency (AATD) is a rare, inherited lung disease which shares features with Chronic Obstructive Pulmonary Disease (COPD) but has a greater burden of proteinase related tissue damage. These proteinases are associated with cardiovascular disease (CVD) in the general population. It is unclear whether patients with AATD have a greater risk of CVD compared to usual COPD, how best to screen for this, and whether neutrophil proteinases are implicated in AATD-associated CVD. This study had three aims. To compare CVD risk in never-augmented AATD patients to non-AATD COPD and healthy controls (HC). To assess relationships between CVD risk and lung physiology. To determine if neutrophil proteinase activity was associated with CVD risk in AATD. Cardiovascular risk was assessed by QRISK2® score and aortic stiffness measurements using carotid-femoral (aortic) pulse wave velocity (aPWV). Medical history, computed tomography scans and post-bronchodilator lung function parameters were reviewed. Systemic proteinase 3 activity was measured. Patients were followed for 4 years, to assess CVD development.

genetics & heredity,medicine, research & experimental
Liver Characterization of a Cohort of Alpha-1 Antitrypsin Deficiency Patients with and without Lung Disease

Naweed Mohammad,Regina Oshins,Tongjun Gu,Virginia Clark,Jorge Lascano,Naziheh Assarzadegan,George Marek,Mark Brantly,Nazli Khodayari

DOI: https://doi.org/10.14218/JCTH.2024.00201

2024-10-28

Abstract:Background and aims: Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder characterized by the misfolding and accumulation of the mutant variant of alpha-1 antitrypsin (AAT) within hepatocytes, which limits its access to the circulation and exposes the lungs to protease-mediated tissue damage. This results in progressive liver disease secondary to AAT polymerization and accumulation, and chronic obstructive pulmonary disease (COPD) due to deficient levels of AAT within the lungs. Our goal was to characterize the unique effects of COPD secondary to AATD on liver disease and gene expression. Methods: A subcohort of AATD individuals with COPD (n = 33) and AATD individuals without COPD (n = 14) were evaluated in this study from our previously reported cross-sectional cohort. We used immunohistochemistry to assess the AATD liver phenotype, and RNA sequencing to explore liver transcriptomics. We observed a distinct transcriptomic profile in liver tissues from AATD individuals with COPD compared to those without. Results: A total of 339 genes were differentially expressed. Canonical pathways related to fibrosis, extracellular matrix remodeling, collagen deposition, hepatocellular damage, and inflammation were significantly upregulated in the livers of AATD individuals with COPD. Histopathological analysis also revealed higher levels of fibrosis and hepatocellular damage in these individuals. Conclusions: Our data supports a relationship between the development of COPD and liver disease in AATD and introduces genes and pathways that may play a role in AATD liver disease when COPD is present. We believe addressing lung impairment and airway inflammation may be an approach to managing AATD-related liver disease.
Immunological and homeostatic pathways of alpha -1 antitrypsin: a new therapeutic potential

Carmen Mazzuca,Laura Vitiello,Silvia Travaglini,Fatima Maurizi,Panaiotis Finamore,Simona Santangelo,Amelia Rigon,Marta Vadacca,Silvia Angeletti,Simone Scarlata

DOI: https://doi.org/10.3389/fimmu.2024.1443297

2024-08-19

Abstract:α -1 antitrypsin (A1AT) is a 52 kDa acute-phase glycoprotein belonging to the serine protease inhibitor superfamily (SERPIN). It is primarily synthesized by hepatocytes and to a lesser extent by monocytes, macrophages, intestinal epithelial cells, and bronchial epithelial cells. A1AT is encoded by SERPINA1 locus, also known as PI locus, highly polymorphic with at least 100 allelic variants described and responsible for different A1AT serum levels and function. A1AT inhibits a variety of serine proteinases, but its main target is represented by Neutrophil Elastase (NE). However, recent attention has been directed towards its immune-regulatory and homeostatic activities. A1AT exerts immune-regulatory effects on different cell types involved in innate and adaptive immunity. Additionally, it plays a role in metal and lipid metabolism, contributing to homeostasis. An adequate comprehension of these mechanisms could support the use of A1AT augmentation therapy in many disorders characterized by a chronic immune response. The aim of this review is to provide an up-to-date understanding of the molecular mechanisms and regulatory pathways responsible for immune-regulatory and homeostatic activities of A1AT. This knowledge aims to support the use of A1AT in therapeutic applications. Furthermore, the review summarizes the current state of knowledge regarding the application of A1AT in clinical and laboratory settings human and animal models.
Liver disease with unknown etiology – have you ruled out alpha-1 antitrypsin deficiency?

Dhiren Patel,Jeffrey Teckman

DOI: https://doi.org/10.1177/2040622321995684

2021-01-01

Therapeutic Advances in Chronic Disease

Abstract:Although a less well-known consequence of alpha-1 antitrypsin deficiency (AATD) liver disease is the second leading cause of death among patients with the condition. The alpha-1 antitrypsin (AAT) protein is produced by hepatocytes within the liver, which retain pathological variants of AAT instead of secreting the proteinase inhibitor into the systemic circulation. This intracellular retention is caused by inefficient folding and polymerization of mutant AAT and the accumulation of these AAT aggregates leads to diverse manifestations of liver disease, which can present differently in both children and adults. The progression from hepatocyte apoptosis to liver inflammation, fibrosis and cirrhosis, and liver failure is still not fully understood, but in older patients, liver disease can surpass lung disease as the principal cause of death. Liver function tests (LFTs) can measure plasma levels of liver enzymes to assess liver function but require careful interpretation. Non-invasive tests are being developed that can detect early liver disease, but liver biopsy is still the gold standard for assessing liver fibrosis once abnormal LFTs have been detected in a patient. Currently, there is no licensed treatment for AATD-related liver disease (intravenous AAT therapy is not indicated for this purpose), but liver transplantation is associated with positive outcomes and may even slow emphysema progression. Therefore, new strategies are being developed to address treatment of AATD-related liver disease, such as accelerating degradation of mutant AAT and assisting hepatocytes in the folding and secretion of mutant AAT, but these approaches remain at early stages of development.

pharmacology & pharmacy
Review article: New developments in biomarkers and clinical drug development in alpha‐1 antitrypsin deficiency‐related liver disease

Rohit Loomba,Ginger Clark,Jeff Teckman,Veeral Ajmera,Cynthia Behling,Mark Brantly,David Brenner,Jeanine D'Armiento,Michael W. Fried,Janani S. Iyer,Mattias Mandorfer,Don C. Rockey,Monica Tincopa,Raj Vuppalanchi,Zobair Younossi,Aleksander Krag,Alice M. Turner,Pavel Strnad

DOI: https://doi.org/10.1111/apt.17967

IF: 9.524

2024-03-23

Alimentary Pharmacology & Therapeutics

Abstract:The 'Biomarker and Clinical Drug Development in AAT: Opportunities and Challenges' forum convened with the goal of improving clinical trial design and facilitating the evaluation of new treatment modalities for alpha‐1 antitrypsin‐related liver disease. Summary Background Alpha‐1 antitrypsin liver disease (AATLD) occurs in a subset of patients with alpha‐1 antitrypsin deficiency. Risk factors for disease progression and specific pathophysiologic features are not well known and validated non‐invasive assessments for disease severity are lacking. Currently, there are no approved treatments for AATLD. Aims To outline existing understanding of AATLD and to identify knowledge gaps critical to improving clinical trial design and development of new treatments. Methods This report was developed following a multi‐stakeholder forum organised by the Alpha‐1 Antitrypsin Deficiency Related Liver Disease Expert Panel in which experts presented an overview of the available literature on this topic. Results AATLD results from a 'gain of toxic function' and primarily manifests in those with the homozygous Pi*ZZ genotype. Accumulation of misfolded 'Z' AAT protein in liver cells triggers intracellular hepatocyte injury which may ultimately lead to hepatic fibrosis. Male gender, age over 50 years, persistently elevated liver tests, concomitant hepatitis B or C virus infection, and metabolic syndrome, including obesity and type 2 diabetes mellitus, are known risk factors for adult AATLD. While the gold standard for assessing AATLD disease activity is liver histology, less invasive measures with low intra‐ and inter‐observer variability are needed. Measurement of liver stiffness shows promise; validated thresholds for staging AATLD are in development. Such advances will help patients by enabling risk stratification and personalised surveillance, along with streamlining the development process for novel therapies. Conclusions This inaugural forum generated a list of recommendations to address unmet needs in the field of AATLD.

pharmacology & pharmacy,gastroenterology & hepatology
Rare variants in alpha 1 antitrypsin deficiency: a systematic literature review

Ilaria Ferrarotti,Marion Wencker,Joanna Chorostowska-Wynimko

DOI: https://doi.org/10.1186/s13023-024-03069-1

2024-02-24

Orphanet Journal of Rare Diseases

Abstract:Alpha 1 Antitrypsin Deficiency (AATD) is a largely underrecognized genetic condition characterized by low Alpha 1 Antitrypsin (AAT) serum levels, resulting from variations in SERPINA1 . Many individuals affected by AATD are thought to be undiagnosed, leading to poor patient outcomes. The Z (c.1096G > A; p.Glu366Lys) and S (c.863A > T; p.Glu288Val) deficiency variants are the most frequently found variants in AATD, with the Z variant present in most individuals diagnosed with AATD. However, there are many other less frequent variants known to contribute to lung and/or liver disease in AATD. To identify the most common rare variants associated with AATD, we conducted a systematic literature review with the aim of assessing AATD variation patterns across the world.

genetics & heredity,medicine, research & experimental
Oxidation‐resistant and Thermostable Forms of Alpha‐1 Antitrypsin from Escherichia Coli Inclusion Bodies

Wei Zhu,Lanfen Li,Mingjing Deng,Bo Wang,Mengfei Li,Guofang Ding,Zuisu Yang,Dan Medynski,Xiaotao Lin,Ying Ouyang,Jirui Lin,Luyuan Li,Xinli Lin

DOI: https://doi.org/10.1002/2211-5463.12515

2018-01-01

FEBS Open Bio

Abstract:Native α1‐antitrypsin (AAT) is a 52‐kDa glycoprotein that acts as an antiprotease and is the physiological inhibitor of neutrophil serine proteases. The main function of AAT is to protect the lung from proteolytic damage induced by inflammation. AAT deficiency (AATD) is a codominant autosomal disorder caused by pathogenic mutations in SERPINA1 gene, leading to reduced levels of serum AAT. The deficiency is known to increase the risk of pulmonary emphysema and chronic obstructive pulmonary disease as a consequence of proteolytic imbalance induced by inflammation, associated in many instances with cigarette smoking and other environmental hazards. Currently, the available therapy for lung disease associated with AATD is serum purified human AAT injected into patients on a weekly basis. It would be advantageous to replace serum‐derived AAT with a recombinant version which is stable and resistant to oxidation. We have expressed AAT in Escherichia coli as inclusion bodies and developed a highly efficient refolding and purification process. We engineered a series of mutant forms of AAT to achieve enhance thermostability and oxidation resistance. Moreover, we synthesized an active form of AAT via cysteine‐pegylation to achieve a markedly extended half‐life in vivo. The resulting molecule, which retains comparable activity to the wild‐type form, is expected to be an improved therapeutic agent for treating hereditary emphysema. In addition, the molecule may also be used to treat other types of emphysema caused by smoking, cystic fibrosis, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease.
Advances in Alpha-1-Antitrypsin Deficiency Liver Disease

Jeffrey H. Teckman,Ajay Jain

DOI: https://doi.org/10.1007/s11894-013-0367-8

2013-12-15

Current Gastroenterology Reports

Abstract:Alpha-1-antitrypsin (a1AT) deficiency is a common, but under–diagnosed, genetic disease. In the classical form, patients are homozygous for the Z mutant of the a1AT gene (called ZZ or PIZZ), which occurs in 1 in 2,000–3,500 births. The mutant Z gene directs the synthesis of large quantities of the mutant Z protein in the liver, which folds abnormally during biogenesis and accumulates intracellularly, rather than being efficiently secreted. The accumulation mutant Z protein within hepatocytes causes liver injury, cirrhosis, and hepatocellular carcinoma via a cascade of chronic hepatocellular apoptosis, regeneration, and end organ injury. There is no specific treatment for a1AT-associated liver disease, other than standard supportive care and transplantation. There is high variability in the clinical manifestations among ZZ homozygous patients, suggesting a strong influence of genetic and environmental modifiers. New insights into the biological mechanisms of intracellular injury have led to new, rational therapeutic approaches.
Polymer-drug conjugates: current status and future trends.

F. Greco,M. Vicent

DOI: https://doi.org/10.2741/2882

Frontiers in Bioscience

Abstract:Polymer conjugates are nano-sized, multi-component constructs already in the clinic as anticancer compounds, both as single agents or as elements of combinations. They have the potential to improve pharmacological therapy of a variety of solid tumors. Polymer-drug conjugation promotes passive tumor targeting by the enhanced permeability and retention (EPR) effect and allows for lysosomotropic drug delivery following endocytic capture. In the first part of this review, we analyze the promising results arising from clinical trials of polymer-bound chemotherapy. The experience gained on these studies provides the basis for the development of a more sophisticated second-generation of polymer conjugates. However, many challenges still lay ahead providing scope to develop and refine this field. The ''technology platform'' of polymer therapeutics allows the development of both new and exciting polymeric materials, the incorporation of novel bioactive agents and combinations thereof to address recent advances in drug therapy. The rational design of polymer drug conjugates is expected to realize the true potential of these "nanomedicines".
30-year mortality of individuals with {alpha}1-antitrypsin deficiency: A Nationwide cohort study

Pedersen,S. S.,Landt,E.,Marott,S.,Turan,G.,Oezdemir,K.,Ellervik,C.,Hviid,T.,Dahl,M.

DOI: https://doi.org/10.1183/13993003.congress-2024.pa4863

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Background: Long-term mortality may be higher in people with alpha-1 antitrypsin deficiency (AATD). Methods: We identified 2712 individuals diagnosed with AATD from 1969 to 2018 and compared them to 26844 persons from the general population matched by age, sex and municipality. We recorded deaths and comorbidities during follow-up using the national Danish Register of Causes of Death and the Danish National Patient Registry. Mortality rate ratios were assessed using cox regression analysis adjusted for age, sex and employment status. Results: The mortality risks for people with AATD were markedly higher than for the comparison cohort during the first year, especially within the first 30 days (18% vs 1.6%). The 30-year mortality rate ratio was 2.38 ([95% CI: 2.21-2.56]) in people with AATD overall, 3.25 ([2.98-3.54]) in patients with AATD and COPD, and 7.04 ([5.32-9.32]) in patients with AATD and liver cirrhosis. The overall 1-10 year and 11-30 year mortality rate ratios improved from 3.75 ([3.23-4.36]) and 3.00 ([2.60-3.47]) in 1969 to 1995 to 1.49 ([1.31-1.70]) and 1.67 ([1.36-2.05]) in 1996-2018, respectively. A similar pattern was seen for patients with AATD and COPD (4.66[3.98-5.46] and 4.26[3.61-5.04] vs 2.03[1.75-2.36] and 2.37[1.87-2.99]), but not in patients with AATD and liver cirrhosis (4.39[2.68-7.20] and 4.06[2.66-6.18] vs 5.61[3.45-9.11] and 3.36[1.11-10.2]). Conclusions: People with alpha-1 antitrypsin deficiency have an increased risk of dying, particularly within the first year after diagnosis or if they have liver cirrhosis or COPD. Mortality beyond 1 year has improved for people with AATD in Denmark, but not for those patients who have comorbid liver cirrhosis.

respiratory system
Cleaning up alpha-1 antitrypsin deficiency related liver disease

Laura Rademacher,Malin Fromme,Pavel Strnad

DOI: https://doi.org/10.1097/MOG.0000000000000919

2023-05-01

Abstract:Purpose of review: Alpha-1 antitrypsin deficiency (AATD) is one of the most common genetic disorders arising due to mutations in alpha-1 antitrypsin (AAT) gene affecting primarily the lung and the liver. This review summarizes the pathophysiology and clinical manifestation of different AATD genotypes and discusses the recent therapeutic developments. The focus is on the severe, rare homozygous Pi∗ZZ and the common heterozygous Pi∗MZ genotype. Recent findings: Pi∗ZZ individuals harbor an up to 20 times higher risk of liver fibrosis and cirrhosis than noncarriers and liver transplantation is currently the only available therapeutic option. AATD constitutes a proteotoxic disorder arising from hepatic AAT accumulation and the currently most promising data come from a phase 2, open-label trial of fazirsiran, a hepatocyte-targeted siRNA. Pi∗MZ subjects display an increased risk of advanced liver disease and at the latter stage, a faster deterioration than individuals without AAT mutation. Summary: Although the fazirsiran data offer a glimpse of hope to AATD patients, a consensus on appropriate study endpoint, a careful patient selection as well as monitoring of long-term safety will be essential for an approval.
S4447 Esophageal and Gastric Variceal Hemorrhage Lead to Discovery of Isolated Hepatic Decompensation Secondary to A1AT Deficiency

Adolfo A. Torres,Lily Cessna,Para Dhulashia,Isha Garala,M'hamed Turki,Tejas Joshi

DOI: https://doi.org/10.14309/01.ajg.0001047156.92637.fd

2024-10-26

The American Journal of Gastroenterology

Abstract:Alpha-1-antitrypsin deficiency (AATD) is an autosomal codominant heritable cause of early-onset emphysema and cirrhosis. The ZZ phenotype is the most common manifestation of AATD and results in the toxic accumulation of abnormal alpha-1-antitrypsin (α1-AT) in the liver – leading to damage and cirrhosis.

gastroenterology & hepatology

[Bisalbuminemia. Review and observations on the acquired form in a patient with myeloma].

Alpha-1 antitrypsin deficiency: A conformational disease associated with lung and liver manifestations

Late Breaking Abstract - Severe alpha-1 antitrypsin deficiency is associated with increased expression of CD8+ T cell markers

Monocyte NLRP3 inflammasome and interleukin-1β activation modulated by alpha-1 antitrypsin therapy in deficient individuals

Alpha-defensins inhibit ERK/STAT3 signaling during monocyte-macrophage differentiation and impede macrophage function

Impact of Hypoxia on Neutrophil Degranulation and Inflammatory Response in Alpha-1 Antitrypsin Deficiency Patients

Alpha-1 antitrypsin deficiency impairs lung antibacterial immunity in mice

The spectrum of clinical sequelae associated with alpha-1 antitrypsin deficiency

The Mechanism of Mitochondrial Injury in Alpha-1 Antitrypsin Deficiency Mediated Liver Disease

Cardiovascular disease in Alpha 1 antitrypsin deficiency: an observational study assessing the role of neutrophil proteinase activity and the suitability of validated screening tools

Liver Characterization of a Cohort of Alpha-1 Antitrypsin Deficiency Patients with and without Lung Disease

Immunological and homeostatic pathways of alpha -1 antitrypsin: a new therapeutic potential

Liver disease with unknown etiology – have you ruled out alpha-1 antitrypsin deficiency?

Review article: New developments in biomarkers and clinical drug development in alpha‐1 antitrypsin deficiency‐related liver disease

Rare variants in alpha 1 antitrypsin deficiency: a systematic literature review

Oxidation‐resistant and Thermostable Forms of Alpha‐1 Antitrypsin from Escherichia Coli Inclusion Bodies

Advances in Alpha-1-Antitrypsin Deficiency Liver Disease

Polymer-drug conjugates: current status and future trends.

30-year mortality of individuals with {alpha}1-antitrypsin deficiency: A Nationwide cohort study

Cleaning up alpha-1 antitrypsin deficiency related liver disease

S4447 Esophageal and Gastric Variceal Hemorrhage Lead to Discovery of Isolated Hepatic Decompensation Secondary to A1AT Deficiency